Search results
Showing 136 to 150 of 551 results for weight management
Cardiovascular risk assessment and lipid modification (QS100)
This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS100Show all sections
Sections for QS100
- Quality statements
- Quality statement 1: Identifying adults who are likely to be at high risk
- Quality statement 2: Diet and lifestyle advice for primary prevention
- Quality statement 3: Lipid-lowering treatment for primary prevention
- Quality statement 4: Assessing response to lipid-lowering treatment
- Quality statement 5: Secondary prevention of cardiovascular disease
- Update information
- About this quality standard
Spinal metastases and metastatic spinal cord compression (NG234)
This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
This guideline covers assessing and managing people aged 14 years and over with coexisting severe mental illness (psychosis) and substance misuse. It aims to help healthcare professionals guide people with psychosis with coexisting substance misuse to stabilise, reduce or stop their substance misuse, to improve treatment adherence and outcomes, and to enhance their lives.
Ustekinumab for treating moderate to severe plaque psoriasis (TA180)
Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.
This guideline covers the short-term management of violence and aggression in adults (aged 18 and over), young people (aged 13 to 17) and children (aged 12 and under). It is relevant for mental health, health and community settings. The guideline aims to safeguard both staff and people who use services by helping to prevent violent situations and providing guidance to manage them safely when they occur.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Pancreatic cancer in adults: diagnosis and management (NG85)
This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.
the barriers to, and facilitators for, participating in lifestyle weight management programmes for overweight and obese children and...
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over (NG36)
This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 or over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. The guideline aims to reduce variation in practice and improve survival.
Golimumab for treating active non-radiographic axial spondyloarthritis (TA497)
Evidence-based recommendations on golimumab (Simponi) for treating active non-radiographic axial spondyloarthritis.
This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.
Gastro-oesophageal reflux in children and young people (QS112)
This quality standard covers managing symptoms of reflux (regurgitation or bringing up feeds) in babies, children and young people (under 18). It also covers diagnosing and managing gastro-oesophageal reflux disease (also called GORD), which is more severe reflux and heartburn. It describes high-quality care in priority areas for improvement.
View quality statements for QS112Show all sections
Sections for QS112
- Quality statements
- Quality statement 1: Information about gastro-oesophageal reflux (GOR) in infants
- Quality statement 2: Breast-fed infants – feeding assessment
- Quality statement 3: Formula-fed infants – stepped-care approach
- Quality statement 4: Alginate therapy
- Quality statement 5: Symptoms that do not need investigation or treatment
- Quality statement 6: Acid-suppressing drugs
- Quality statement 7: Upper gastrointestinal (GI) contrast study
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.